Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis

BACKGROUND: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors’ institution suggested men who use PDE5i f...

Descripción completa

Detalles Bibliográficos
Autores principales: Machen, G. Luke, Rajab, M. Hasan, Pruszynski, Jessica, Coffield, K. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673806/
https://www.ncbi.nlm.nih.gov/pubmed/29184786
http://dx.doi.org/10.21037/tau.2017.06.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673806/
https://www.ncbi.nlm.nih.gov/pubmed/29184786
http://dx.doi.org/10.21037/tau.2017.06.02

Ejemplares similares